Intranasal IgG Delivery via Olfactory Pathway for CNS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating central nervous system disorders like Alzheimer's disease using intravenous immunoglobulin G (IgG) are inconvenient, cause systemic side effects, and face challenges in delivering IgG across the blood-brain barrier, leading to inefficiencies and increased demand for a limited resource.
Innovation Solution
Intranasal administration of pooled human immunoglobulin G directly to the brain, bypassing the blood-brain barrier, allowing targeted delivery and reducing the necessary dose, thereby minimizing systemic exposure and adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous immunoglobulin G is administered to treat CNS disorders, then therapeutic effect is achieved, but systemic side effects occur and the blood-brain barrier cannot be efficiently crossed
Solution Approach 1:
The patent uses the nasal cavity and olfactory nerve pathway as an intermediary route to deliver IgG directly to the brain, bypassing the blood-brain barrier and avoiding systemic circulation. This mediator pathway enables targeted CNS delivery without the harmful systemic effects of intravenous administration.
Solution Approach 2:
The patent segments the delivery system into distinct anatomical pathways: nasal cavity administration, olfactory epithelium absorption, and direct brain delivery via olfactory nerves. This segmentation separates the therapeutic delivery route from systemic circulation, preventing systemic side effects while maintaining CNS therapeutic effect.
2Reliability
If intravenous immunoglobulin G is administered to treat CNS disorders, then therapeutic effect is achieved, but IgG cannot efficiently cross the blood-brain barrier
Solution Approach 1:
The olfactory nerve pathway serves as a direct intermediary conduit from the nasal cavity to the brain, eliminating the need for IgG to cross the blood-brain barrier. This intermediary route provides efficient direct access to CNS tissues.
Solution Approach 2:
Instead of attempting to cross the blood-brain barrier from the bloodstream (the conventional approach), the patent inverts the delivery route by accessing the brain directly from the nasal cavity through olfactory nerves, completely bypassing the barrier problem.
3Reliability
If intravenous immunoglobulin G is administered to treat CNS disorders, then therapeutic effect is achieved, but the demand for limited IgG resource increases
Solution Approach 1:
The patent segments the IgG delivery to concentrate it directly at the CNS target site rather than distributing it systemically. This localized delivery through the nasal-olfactory pathway reduces the total quantity of IgG required to achieve therapeutic effect in the brain.
Solution Approach 2:
The patent creates local high concentration of IgG directly at the CNS target through nasal administration, rather than relying on systemic distribution. This local quality enhancement achieves therapeutic effect with lower total dose, conserving the limited IgG resource.
Data Source
AI summary
The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.